Comparative review of topical ophthalmic antibacterial preparations.
The choice of an antibacterial is based on considerations of pharmacodynamic, pharmacokinetic and bacteriological characteristics, risk of selecting resistant mutants, and cost. In this article we review 16 commercially available ophthalmic antibacterial preparations. Fusidic acid and bacitracin are selective for gram-positive bacteria whereas polymyxin B targets gram-negative species. Aminoglycosides and quinolones are broad spectrum antibacterials. The widespread use of an antibacterial increases risks of selecting resistance to it. Acquired resistance is well documented for fusidic acid and rifamycin, and newly described for quinolones. The bioavailability of an antibacterial agent depends on the target bacterial species, the site of infection and the integrity of the haemato-aqueous barrier. Some agents (fusidic acid, quinolones) penetrate the cornea, passing into the anterior chamber of normal eyes at therapeutic concentrations, whereas others (polymixin B, bacitracin) have no penetrating powers and remain at the surface of the eye. Toxicity is mostly manifested by allergic reactions to excipients or active ingredients in topical antibacterial preparations. A few cases of haematological toxicity have brought suspicion on topical chloramphenicol, but the link has yet to be proven. Erythromycin and polymyxin B are probably okay to use as topical applications in pregnant women and nursing mothers. Costs of treatment must be evaluated as a whole (regimen, drug associations). Prices for a bottle of eyedrops may vary 3-fold. The cheapest drugs include chloramphenicol, polymyxin B and gentamicin, the most expensive being fusidic acid and the quinolones.
Robert
P Y
PY
Service d'Ophtalmologie, Centre Hospitalier Universitaire de Limoge, Hopital Universitaire Dupuytren, Limoges, France.
Adenis
J P
JP
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D002701:Chloramphenicol / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D015818:Eye Infections, Bacterial / Q000188:drug therapy*; D005672:Fusidic Acid / Q000008:administration & dosage / Q000191:economics; D005839:Gentamicins / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D006801:Humans; D015363:Quinolones / Q000008:administration & dosage; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D014141:Trachoma / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D015363:Quinolones; D005672:Fusidic Acid; D002701:Chloramphenicol; D014031:Tobramycin